GlassScriptPhysician profile
Wayne A Solley
NPI 1528042447
$20,097.48
in general payments reported to CMS, 2019-2025
21 companies · $2,074 in 2025
The $2,074 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.70 · 2020: $1,518 · 2021: $547 · 2022: $308 · 2023: $2,839 · 2024: $13K · 2025: $2,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Travel and Lodging: $3,333 · Food and Beverage: $1,939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,362.50 |
| Travel and Lodging | $3,333.06 |
| Food and Beverage | $1,939.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $13,806.91 | 2023-2024 | Pavblu, Tepezza |
| Ocular Therapeutix, INC. | $2,163.94 | 2024-2025 | Dextenza |
| Carl Zeiss Meditec, INC. | $1,459.07 | 2020 | |
| Genentech USA, INC. | $497.57 | 2020-2024 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $480.66 | 2023-2024 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $392.72 | 2019-2024 | Eylea Hd, Eylea |
| Horizon Therapeutics Plc | $266.25 | 2019-2023 | Tepezza |
| Coherus Oncology, INC. | $178.51 | 2022-2024 | |
| Abbvie INC. | $167.26 | 2022-2024 | Ozurdex |
| Astellas Pharma US INC | $165.70 | 2023-2024 | Izervay |
| Novartis Pharmaceuticals Corporation | $161.36 | 2019-2021 | |
| Alimera Sciences, INC. | $153.40 | 2022-2023 | Yutiq |
| Harrow Eye, LLC | $50.15 | 2024 | Iheezo, Triesence |
| Eyepoint US, INC. | $47.25 | 2022-2023 | |
| Allergan, INC. | $35.59 | 2019-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $31.01 | 2021-2022 | |
| Sandoz INC. | $24.64 | 2024 | Cimerli |
| Bausch & Lomb Americas INC. | $15.49 | 2024 | Xipere |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Solley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.